http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101871847-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-347 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2016-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101871847-B1 |
| titleOfInvention | A biomarker composition for diagnosis of lupus nephritis comprising Immunoglobulin binding protein 1 |
| abstract | The present invention provides a biomarker for diagnosing Lupus nephritis including IGBP1, and a composition for diagnosis and treatment of Lupus nephritis. When the biomarker for diagnosing Lupus nephritis including IGFP1 of the present invention is used, subtypes I to VI of Lupus nephritis can be diagnosed by using blood or urine. In addition, we confirmed the possibility of predicting drug response by confirming the activity and chronicity of patients with lupus nephritis. In addition, when a patient with lymphocytic nephritis is re-aged after the treatment, the activity and the degree of chronicity can be confirmed using the marker of the present invention, thereby reducing the retry of biopsy. In addition, if the biopsy biopsy can not be performed, the possibility of the prognosis of the prognosis of Lupus nephritis type III or IV can be predicted by using the marker of the present invention. In addition, the degree of renal damage in patients with lymphocytic nephritis can be predicted, and information on timely use of immunosuppressants and therapeutic agents can be provided. Further, by confirming the effect of IGBP1 on the incidence and exacerbation of lupus nephritis, the IGBP1 inhibitor can inhibit renal tissue damage caused by Lupus nephritis and thus can be utilized as a novel therapeutic agent for Lupus nephritis. |
| priorityDate | 2016-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 73.